Literature DB >> 16179497

Quantitative and spatial measurements of telomerase reverse transcriptase expression within normal and malignant human breast tissues.

William C Hines1, Alexandra M Fajardo, Nancy E Joste, Marco Bisoffi, Jeffrey K Griffith.   

Abstract

The enzyme telomerase catalyzes the de novo synthesis of telomere repeats, thereby maintaining telomere length, which is necessary for unlimited cellular proliferation. Telomerase reverse transcriptase (TERT), the catalytic domain of telomerase, is the rate-limiting factor for telomerase activity and is expressed in virtually all tumors. Thus, TERT has been proposed as a marker with diagnostic and prognostic potential in breast cancer as well as a basis for breast cancer therapeutics. In these contexts, it is important to define the sites and extent of TERT expression in normal and cancerous human breast tissues. In this study, levels of TERT mRNA were measured within a set of 36 breast carcinomas and 5 normal breast samples by quantitative real-time reverse transcription-PCR, and we subsequently identified and characterized the cells expressing TERT mRNA within these tissues using in situ hybridization. The results show that (a) detectable TERT mRNA expression is specific to the epithelial cells; (b) TERT is expressed in both normal and malignant breast tissues; (c) the pattern and level of TERT expression are heterogeneous, with approximately 75% of tumors expressing bulk TERT mRNA levels equal to or less than those within normal breast tissue; and (d) tumors expressing above-normal levels of TERT mRNA are more likely to be histopathologic grade 3 (P = 0.002), contain high fraction of cells in S phase (P = 0.004), and have increased levels of MYC mRNA (P = 0.034).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16179497     DOI: 10.1158/1541-7786.MCR-05-0031

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  12 in total

1.  Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression.

Authors:  Ekta Khattar; Pavanish Kumar; Chia Yi Liu; Semih Can Akıncılar; Anandhkumar Raju; Manikandan Lakshmanan; Julien Jean Pierre Maury; Yu Qiang; Shang Li; Ern Yu Tan; Kam M Hui; Ming Shi; Yuin Han Loh; Vinay Tergaonkar
Journal:  J Clin Invest       Date:  2016-09-19       Impact factor: 14.808

2.  p16(INK4a) -mediated suppression of telomerase in normal and malignant human breast cells.

Authors:  Alexey V Bazarov; Marjolein Van Sluis; William C Hines; Ekaterina Bassett; Alain Beliveau; Eric Campeau; Rituparna Mukhopadhyay; Won Jae Lee; Sonya Melodyev; Yuri Zaslavsky; Leonard Lee; Francis Rodier; Agustin Chicas; Scott W Lowe; Jean Benhattar; Bing Ren; Judith Campisi; Paul Yaswen
Journal:  Aging Cell       Date:  2010-07-14       Impact factor: 9.304

Review 3.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

4.  Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors.

Authors:  Kristina A Trujillo; Christopher M Heaphy; Minh Mai; Keith M Vargas; Anna C Jones; Phung Vo; Kimberly S Butler; Nancy E Joste; Marco Bisoffi; Jeffrey K Griffith
Journal:  Int J Cancer       Date:  2011-02-11       Impact factor: 7.396

5.  Breast field cancerization: isolation and comparison of telomerase-expressing cells in tumor and tumor adjacent, histologically normal breast tissue.

Authors:  Kristina A Trujillo; William C Hines; Keith M Vargas; Anna C Jones; Nancy E Joste; Marco Bisoffi; Jeffrey K Griffith
Journal:  Mol Cancer Res       Date:  2011-07-20       Impact factor: 5.852

6.  MYC and Breast Cancer.

Authors:  Jinhua Xu; Yinghua Chen; Olufunmilayo I Olopade
Journal:  Genes Cancer       Date:  2010-06

7.  Genomic instability demonstrates similarity between DCIS and invasive carcinomas.

Authors:  Christopher M Heaphy; Marco Bisoffi; Nancy E Joste; Kathy B Baumgartner; Richard N Baumgartner; Jeffrey K Griffith
Journal:  Breast Cancer Res Treat       Date:  2008-09-11       Impact factor: 4.872

Review 8.  MYC in breast tumor progression.

Authors:  Yinghua Chen; Olufunmilayo I Olopade
Journal:  Expert Rev Anticancer Ther       Date:  2008-10       Impact factor: 4.512

9.  Molecular characterisation of breast cancer patients at high and low recurrence risk.

Authors:  Serena Bonin; Davide Brunetti; Elena Benedetti; Isabella Dotti; Nader Gorji; Giorgio Stanta
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

10.  Coordinate regulation between expression levels of telomere-binding proteins and telomere length in breast carcinomas.

Authors:  Kimberly S Butler; William C Hines; Christopher M Heaphy; Jeffrey K Griffith
Journal:  Cancer Med       Date:  2012-07-24       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.